Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Retained Earnings: 2019-2024

Historic Retained Earnings for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to -$633.7 million.

  • C4 Therapeutics' Retained Earnings fell 19.88% to -$718.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$718.2 million, marking a year-over-year decrease of 19.88%. This contributed to the annual value of -$633.7 million for FY2024, which is 19.93% down from last year.
  • Latest data reveals that C4 Therapeutics reported Retained Earnings of -$633.7 million as of FY2024, which was down 19.93% from -$528.4 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Retained Earnings ranged from a high of -$183.8 million in FY2020 and a low of -$633.7 million during FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$528.4 million (2023), whereas its average is -$519.3 million.
  • Data for C4 Therapeutics' Retained Earnings shows a maximum YoY crashed of 56.46% (in 2020) over the last 5 years.
  • Over the past 5 years, C4 Therapeutics' Retained Earnings (Yearly) stood at -$183.8 million in 2020, then plummeted by 45.64% to -$267.7 million in 2021, then slumped by 47.88% to -$395.9 million in 2022, then tumbled by 33.47% to -$528.4 million in 2023, then dropped by 19.93% to -$633.7 million in 2024.